Miraculins Inc (MCUIF) 0.1550 $MCUIF
Miraculins Completes Share Consolidation
Marketwire - Fri Jan 24, 3:31PM CST
Miraculins Inc. (TSX VENTURE: MOM) ("Miraculins" or the "Company"
, a medical diagnostic company focused on acquiring, developing and commercializing diagnostic and risk assessment technologies for unmet clinical needs, announces that, further to its news release of January 13, 2014, the TSX Venture Exchange has approved the consolidation of the Company's issued and outstanding common shares ("Common Shares" on the basis of ten pre-consolidation Common Shares for every one post-consolidation Common Share and the Company has proceeded with the consolidation. Effective at the opening of the market on January 27, 2014, Miraculins' shares will commence trading on the TSX Venture Exchange on a consolidated basis under the new CUSIP number 60462L207. The Company's name and trading symbol will not change as a result of the consolidation. The Company will have approximately 12,492,010 Common Shares issued and outstanding as a result of the consolidation. Letters of transmittal with respect to the consolidation will be sent to registered shareholders by CST Trust Company, the Company's Transfer Agent.
Miraculins Releases CEO Letter to Shareholders
Marketwire - Mon Jan 20, 6:19AM CST
Miraculins Inc. (TSX VENTURE: MOM), ("Miraculins" or the "Company" a medical diagnostic company focused on acquiring, developing and commercializing diagnostic and risk assessment technologies for unmet clinical needs, today issues the following letter to shareholders from Company President & CEO Christopher Moreau:
Miraculins Announces Proposed Ten to One Share Consolidation
Marketwire - Mon Jan 13, 5:30AM CST
Miraculins Inc. (TSX VENTURE: MOM), ("Miraculins" or the "Company" a medical diagnostic company focused on acquiring, developing and commercializing diagnostic and risk assessment technologies for unmet clinical needs, announces that its Board of Directors have approved a consolidation of the Company's common shares ("Common Shares" on the basis of ten pre-consolidation Common Shares for each one post-consolidation Common Share, subject to the approval of the TSX Venture Exchange.
Miraculins Announces Closing of First Tranche of Non-Convertible Secured Loan
Marketwire - Fri Jan 10, 3:31PM CST
Miraculins Inc. (TSX VENTURE: MOM) ("Miraculins" or the "Company" , a medical diagnostic company focused on acquiring, developing and commercializing diagnostic and risk assessment technologies for unmet clinical needs, announces that it has closed an initial tranche under the non-convertible secured loan with a third party lender (the "Lender" as previously announced on December 23, 2013 (the "Loan" , receiving an advance of CDN$250,000 from the Lender.
Miraculins and Cachet Pharmaceutical Agree to 30-Day Extension on Letter of Intent to Continue Negotiation of Licensing Rights for SCOUT DS(R) Diabetes Test in China
Marketwire - Tue Dec 31, 5:31AM CST
Miraculins Inc. (TSX VENTURE: MOM) ("Miraculins" or the "Company" , a medical diagnostic company focused on acquiring, developing and commercializing diagnostic and risk assessment technologies for unmet clinical needs, today announces that the non-binding Letter of Intent (the "LOI" the Company executed with Cachet Pharmaceutical Co. Ltd. ("Cachet" on September 30, 2013, to provide a non-exclusive 90-day negotiation period for Cachet to acquire an exclusive license to commercialize the Company's Scout DS(R) Non-Invasive Diabetes Screening Test in Mainland China, has been extended by mutual agreement of the parties for an additional 30-day period ending January 30, 2014.
Miraculins Announces First Closing of Private Placement Offering
Marketwire - Fri Sep 20, 4:06PM CDT
Miraculins Inc. (TSX VENTURE: MOM), (the "Company" , a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, is pleased to announce the first close of a private placement offering (the "Offering" with aggregate gross proceeds to the Company of $430,000 from the sale of 7,166,667 units ("Units" at a price of $0.06 per Unit. Each Unit is comprised of one common share of the Company (a "Share" and one half of one Share purchase warrant (a "Warrant" .
Miraculins' SCOUT DS(R) Non-Invasive Diabetes Screening Test to be Piloted by Major Canadian Supermarket Chain
Marketwire - Mon Sep 16, 5:31AM CDT
Miraculins Inc. (TSX VENTURE: MOM), ("Miraculins" or the "Company" a medical diagnostic company focused on acquiring, developing and commercializing diagnostic and risk assessment technologies for unmet clinical needs, today announces that a major Canadian supermarket chain, in collaboration with Pear Healthcare Solutions ("Pear" , a leading provider of in-pharmacy health screening and educational services to the Canadian pharmacy community, will be conducting a special pilot of the Miraculins' SCOUT DS(R) Non-Invasive Diabetes Screening technology as part of a series of pharmacy diabetes clinics to be held at 35 store locations in fall 2013.
Miraculins Announces Private Placement Offering
Marketwire - Thu Sep 12, 5:31AM CDT
Miraculins Inc. (TSX VENTURE: MOM), ("Miraculins" or the "Company" a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, today announces a non-brokered private placement offering (the "Offering" of up to 16,666,666 units ("Units" at a price of $0.06 per Unit for gross proceeds of up to $1,000,000. Each Unit will be comprised of one common share of the Company (a "Share" and one half of one Share purchase warrant. Each whole warrant (a "Warrant" will entitle the holder to purchase one Share at a price of $0.10 per Share for a period of 12 months from the date the Warrant is issued.
Miraculins Announces Publication of Comprehensive Review Article on Skin Cholesterol and Its Link to Increased Cardiovascular Risk
Marketwire - Mon Sep 09, 5:31AM CDT
Miraculins Inc. (TSX VENTURE: MOM), ("Miraculins" or the "Company" a medical diagnostic company focused on acquiring, developing and commercializing diagnostic and risk assessment technologies for unmet clinical needs, announces today the publication of a review article entitled "The Relationship Between Skin Cholesterol Testing and Parameters of Cardiovascular Risk: A Systematic Review" authored by A. Yashar Tashakkor, MD, and G. B. John Mancini, MD, FRCPC of the Department of Medicine (Division of Cardiology), University of British Columbia.
Miraculins Announces H-E-B Store Locations for Its PreVu(R) Skin Cholesterol Test Pilot in Texas
Marketwire - Thu Sep 05, 5:31AM CDT
Miraculins Inc. (TSX VENTURE: MOM), ("Miraculins" or the "Company" , a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, announces today the 20 store locations where H-E-B, the #1 food retailer in South and Central Texas and the State's largest private company, will be conducting a pilot launch of the Company's PreVu(R) Non-Invasive Skin Cholesterol Point of Care (POC) Test this fall. This is the first such launch of the product into the United States.
Miraculins Completes Share Consolidation
Marketwire - Fri Jan 24, 3:31PM CST
Miraculins Inc. (TSX VENTURE: MOM) ("Miraculins" or the "Company"
, a medical diagnostic company focused on acquiring, developing and commercializing diagnostic and risk assessment technologies for unmet clinical needs, announces that, further to its news release of January 13, 2014, the TSX Venture Exchange has approved the consolidation of the Company's issued and outstanding common shares ("Common Shares" on the basis of ten pre-consolidation Common Shares for every one post-consolidation Common Share and the Company has proceeded with the consolidation. Effective at the opening of the market on January 27, 2014, Miraculins' shares will commence trading on the TSX Venture Exchange on a consolidated basis under the new CUSIP number 60462L207. The Company's name and trading symbol will not change as a result of the consolidation. The Company will have approximately 12,492,010 Common Shares issued and outstanding as a result of the consolidation. Letters of transmittal with respect to the consolidation will be sent to registered shareholders by CST Trust Company, the Company's Transfer Agent. Miraculins Releases CEO Letter to Shareholders
Marketwire - Mon Jan 20, 6:19AM CST
Miraculins Inc. (TSX VENTURE: MOM), ("Miraculins" or the "Company"
a medical diagnostic company focused on acquiring, developing and commercializing diagnostic and risk assessment technologies for unmet clinical needs, today issues the following letter to shareholders from Company President & CEO Christopher Moreau: Miraculins Announces Proposed Ten to One Share Consolidation
Marketwire - Mon Jan 13, 5:30AM CST
Miraculins Inc. (TSX VENTURE: MOM), ("Miraculins" or the "Company"
a medical diagnostic company focused on acquiring, developing and commercializing diagnostic and risk assessment technologies for unmet clinical needs, announces that its Board of Directors have approved a consolidation of the Company's common shares ("Common Shares" on the basis of ten pre-consolidation Common Shares for each one post-consolidation Common Share, subject to the approval of the TSX Venture Exchange. Miraculins Announces Closing of First Tranche of Non-Convertible Secured Loan
Marketwire - Fri Jan 10, 3:31PM CST
Miraculins Inc. (TSX VENTURE: MOM) ("Miraculins" or the "Company"
, a medical diagnostic company focused on acquiring, developing and commercializing diagnostic and risk assessment technologies for unmet clinical needs, announces that it has closed an initial tranche under the non-convertible secured loan with a third party lender (the "Lender" as previously announced on December 23, 2013 (the "Loan" , receiving an advance of CDN$250,000 from the Lender. Miraculins and Cachet Pharmaceutical Agree to 30-Day Extension on Letter of Intent to Continue Negotiation of Licensing Rights for SCOUT DS(R) Diabetes Test in China
Marketwire - Tue Dec 31, 5:31AM CST
Miraculins Inc. (TSX VENTURE: MOM) ("Miraculins" or the "Company"
, a medical diagnostic company focused on acquiring, developing and commercializing diagnostic and risk assessment technologies for unmet clinical needs, today announces that the non-binding Letter of Intent (the "LOI" the Company executed with Cachet Pharmaceutical Co. Ltd. ("Cachet" on September 30, 2013, to provide a non-exclusive 90-day negotiation period for Cachet to acquire an exclusive license to commercialize the Company's Scout DS(R) Non-Invasive Diabetes Screening Test in Mainland China, has been extended by mutual agreement of the parties for an additional 30-day period ending January 30, 2014. Miraculins Announces First Closing of Private Placement Offering
Marketwire - Fri Sep 20, 4:06PM CDT
Miraculins Inc. (TSX VENTURE: MOM), (the "Company"
, a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, is pleased to announce the first close of a private placement offering (the "Offering" with aggregate gross proceeds to the Company of $430,000 from the sale of 7,166,667 units ("Units" at a price of $0.06 per Unit. Each Unit is comprised of one common share of the Company (a "Share" and one half of one Share purchase warrant (a "Warrant" . Miraculins' SCOUT DS(R) Non-Invasive Diabetes Screening Test to be Piloted by Major Canadian Supermarket Chain
Marketwire - Mon Sep 16, 5:31AM CDT
Miraculins Inc. (TSX VENTURE: MOM), ("Miraculins" or the "Company"
a medical diagnostic company focused on acquiring, developing and commercializing diagnostic and risk assessment technologies for unmet clinical needs, today announces that a major Canadian supermarket chain, in collaboration with Pear Healthcare Solutions ("Pear" , a leading provider of in-pharmacy health screening and educational services to the Canadian pharmacy community, will be conducting a special pilot of the Miraculins' SCOUT DS(R) Non-Invasive Diabetes Screening technology as part of a series of pharmacy diabetes clinics to be held at 35 store locations in fall 2013. Miraculins Announces Private Placement Offering
Marketwire - Thu Sep 12, 5:31AM CDT
Miraculins Inc. (TSX VENTURE: MOM), ("Miraculins" or the "Company"
a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, today announces a non-brokered private placement offering (the "Offering" of up to 16,666,666 units ("Units" at a price of $0.06 per Unit for gross proceeds of up to $1,000,000. Each Unit will be comprised of one common share of the Company (a "Share" and one half of one Share purchase warrant. Each whole warrant (a "Warrant" will entitle the holder to purchase one Share at a price of $0.10 per Share for a period of 12 months from the date the Warrant is issued. Miraculins Announces Publication of Comprehensive Review Article on Skin Cholesterol and Its Link to Increased Cardiovascular Risk
Marketwire - Mon Sep 09, 5:31AM CDT
Miraculins Inc. (TSX VENTURE: MOM), ("Miraculins" or the "Company"
a medical diagnostic company focused on acquiring, developing and commercializing diagnostic and risk assessment technologies for unmet clinical needs, announces today the publication of a review article entitled "The Relationship Between Skin Cholesterol Testing and Parameters of Cardiovascular Risk: A Systematic Review" authored by A. Yashar Tashakkor, MD, and G. B. John Mancini, MD, FRCPC of the Department of Medicine (Division of Cardiology), University of British Columbia. Miraculins Announces H-E-B Store Locations for Its PreVu(R) Skin Cholesterol Test Pilot in Texas
Marketwire - Thu Sep 05, 5:31AM CDT
Miraculins Inc. (TSX VENTURE: MOM), ("Miraculins" or the "Company"
, a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, announces today the 20 store locations where H-E-B, the #1 food retailer in South and Central Texas and the State's largest private company, will be conducting a pilot launch of the Company's PreVu(R) Non-Invasive Skin Cholesterol Point of Care (POC) Test this fall. This is the first such launch of the product into the United States. 
